Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Blueprint Medicines Corp (BPMC)

Blueprint Medicines Corp (BPMC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,980,973
  • Shares Outstanding, K 63,526
  • Annual Sales, $ 249,380 K
  • Annual Income, $ -506,980 K
  • EBIT $ -276 M
  • EBITDA $ -282 M
  • 60-Month Beta 0.59
  • Price/Sales 24.61
  • Price/Cash Flow N/A
  • Price/Book 19.60

Options Overview Details

View History
  • Implied Volatility 49.87% ( +6.36%)
  • Historical Volatility 44.80%
  • IV Percentile 55%
  • IV Rank 41.68%
  • IV High 74.91% on 01/05/24
  • IV Low 31.96% on 12/07/23
  • Put/Call Vol Ratio 1.96
  • Today's Volume 5,264
  • Volume Avg (30-Day) 1,099
  • Put/Call OI Ratio 1.09
  • Today's Open Interest 42,803
  • Open Int (30-Day) 40,394

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.49
  • Number of Estimates 11
  • High Estimate 1.40
  • Low Estimate -0.96
  • Prior Year -1.82
  • Growth Rate Est. (year over year) +73.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
80.68 +16.70%
on 10/29/24
103.55 -9.08%
on 11/11/24
+7.68 (+8.88%)
since 10/22/24
3-Month
80.68 +16.70%
on 10/29/24
103.55 -9.08%
on 11/11/24
+0.64 (+0.68%)
since 08/22/24
52-Week
66.61 +41.35%
on 11/24/23
121.90 -22.76%
on 07/16/24
+27.14 (+40.50%)
since 11/22/23

Most Recent Stories

More News
Blueprint Medicines: Q3 Earnings Snapshot

Blueprint Medicines: Q3 Earnings Snapshot

BPMC : 94.15 (-2.56%)
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma

For Immediate ReleaseChicago, IL – October 25, 2024 – Today, Zacks Equity Research discusses Exelixis, Inc, EXEL, Blueprint Medicines BPMC, CRISPR Therapeutics CRSP, Amicus Therapeutics FOLD and Verona...

FOLD : 9.66 (+1.68%)
CRSP : 47.88 (+3.43%)
VRNA : 38.81 (+2.51%)
EXEL : 35.61 (+2.24%)
BPMC : 94.15 (-2.56%)
5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright

It has been a decent year for the biotech industry so far, buoyed by new drug approvals and positive regulatory/pipeline updates. The third-quarter earnings season has just kicked off, with most major...

FOLD : 9.66 (+1.68%)
CRSP : 47.88 (+3.43%)
VRNA : 38.81 (+2.51%)
EXEL : 35.61 (+2.24%)
BPMC : 94.15 (-2.56%)
Blueprint Medicines: Q2 Earnings Snapshot

Blueprint Medicines: Q2 Earnings Snapshot

BPMC : 94.15 (-2.56%)
Blueprint Medicines: Q1 Earnings Snapshot

Blueprint Medicines: Q1 Earnings Snapshot

BPMC : 94.15 (-2.56%)
Blueprint Medicines: Q4 Earnings Snapshot

Blueprint Medicines: Q4 Earnings Snapshot

BPMC : 94.15 (-2.56%)
Chart of the Day: Does Blueprint Medicines Have a Blueprint for Success?

The Chart of the Day belongs to the cancer biomedical company Blueprint Medicines (BPMC) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical...

BPMC : 94.15 (-2.56%)
Why Blueprint Medicines Stock Soared Today

The precision-treatment company saw stronger-than-expected sales in its first full quarter following the launch of Ayvakit.

BPMC : 94.15 (-2.56%)
Blueprint Medicines: Q3 Earnings Snapshot

Blueprint Medicines: Q3 Earnings Snapshot

BPMC : 94.15 (-2.56%)
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective October 1, 2023, the Compensation Committee of Blueprint...

BPMC : 94.15 (-2.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Blueprint Medicines Corporation is a biopharmaceutical company focused on developing the potentially transformational precision medicines to address patients with genomically defined cancers and rare diseases.

See More

Key Turning Points

3rd Resistance Point 101.19
2nd Resistance Point 99.76
1st Resistance Point 96.96
Last Price 94.15
1st Support Level 92.73
2nd Support Level 91.30
3rd Support Level 88.50

See More

52-Week High 121.90
Fibonacci 61.8% 100.78
Fibonacci 50% 94.26
Last Price 94.15
Fibonacci 38.2% 87.73
52-Week Low 66.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar